TREA

97770271 - EARLI

Follow

Information

  • Trademark
  • 97770271
  • Serial Number
    97770271
  • Filing Date
    January 27, 2023
    2 years ago
  • Transaction Date
    March 07, 2025
    3 days ago
  • Status Date
    March 06, 2025
    4 days ago
  • Published for Opposition Date
    October 15, 2024
    4 months ago
  • Location Date
    November 26, 2024
    3 months ago
  • Status Code
    730
  • Current Location
    INTENT TO USE SECTION
    Employee Name
    PURATH,ANICKA S
  • Attorney Docket Number
    34601-00070
    Attorney Name
    Connie Ellerbach
    Law Office Assigned Location Code
    L10
  • Owners
Information
Mark Drawing Code
4
Mark Identification
EARLI
Case File Statements
  • GS0091: Scientific apparatus in the nature of medical laboratory research instruments for the detection and localization of diseases, pathogens and toxins in a biological sample obtained from humans and animals for research use
  • GS0051: Pharmaceutical and veterinary preparations and products for medical purposes for the prevention, detection, localization, and treatment of infectious viral-based, diseases, infectious bacterial-based diseases, infectious fungal-based diseases, autoimmune diseases, allergies, heart- and vascular-based diseases, cerebrovascular disease, neurological disorders and diseases, metabolic diseases, genetic diseases, blood-based diseases, kidney diseases, pancreatic diseases, muscular and neuromuscular diseases, gastrointestinal diseases and conditions, and toxins in the body tissue and fluids of humans and animals; Drug delivery agents in the form of tablet coatings, edible wafers, powders, tablets, and capsules that facilitate the delivery of other pharmaceutical preparations into human and animal bodies; Reagents for use in therapeutics for medical purposes; Diagnostic and therapeutic preparations for medical purposes, namely, diagnostic preparations and therapeutic pharmaceutical preparations for detecting and treating infectious viral-based diseases, infectious bacterial-based diseases, infectious fungal based diseases, autoimmune diseases, allergies, heart- and vascular-based diseases, cerebrovascular disease, neurological disorders and diseases, metabolic diseases, genetic diseases, blood-based diseases, kidney diseases, pancreatic diseases, muscular and neuromuscular diseases, and gastrointestinal diseases and conditions, and for detecting the presence of toxins in body tissue and fluids; medical diagnostic reagents and assays for testing of body fluids, reagents for medical use, diagnostic reagents for medical uses, enzymes for medical purposes, and diagnostic nucleotides for medical use; medical diagnostic assays for testing of body fluids, biological preparations in the nature of recombinant nucleic acid vectors, biological preparations in the nature of recombinant viral vectors, transfection agents being reagents for medical use, reagents for medical use, enzymes for medical purposes, and diagnostic nucleotides for medical purposes, and diagnostic nucleotides for medical use, all for the foregoing being for the treatment of infectious viral-based, diseases, infectious bacterial-based diseases, infectious fungal-based diseases, autoimmune diseases, allergies, heart- and vascular-based diseases, cerebrovascular disease, neurological disorders and diseases, metabolic diseases, genetic diseases, blood-based diseases, kidney diseases, pancreatic diseases, muscular and neuromuscular diseases, gastrointestinal diseases and conditions, and toxins in the body tissue and fluids of humans and animals; medical diagnostic assays and reagents for testing of body fluids, reagents for medical use, enzymes for medical purposes, and diagnostic nucleotides for medical use, all the forgoing for medical diagnostic and treatment purposes, namely, for use in detecting and treating infectious viral-based diseases, infectious bacterial-based diseases, infectious fungal-based diseases, autoimmune diseases, allergies, heart- and vascular-based diseases, cerebrovascular disease, neurological disorders and diseases, metabolic diseases, genetic diseases, blood-based diseases, kidney diseases, pancreatic diseases, muscular and neuromuscular diseases, and gastrointestinal diseases and conditions, and for use in detecting the presence of toxins in body tissue and fluids and for eliminating toxins from body tissue and fluids; therapeutic diagnostic agents for medical purposes, therapeutic agents in the nature of therapeutic pharmaceuticals for the treatment of cancer, infectious viral-based diseases, infectious bacterial-based diseases, infectious fungal-based diseases, autoimmune diseases, allergies, respiratory diseases, heart- and vascular-based diseases, cerebrovascular disease, neurological disorders and diseases, metabolic diseases, genetic diseases, blood-based diseases, kidney diseases, liver and pancreatic diseases, muscular and neuromuscular diseases, and gastrointestinal diseases and conditions, and therapeutic agents being therapeutic diagnostic and pharmaceutical preparations for detecting the presence of toxins in body tissue and fluid and for eliminating toxins from body tissue and fluids; therapeutic agents for medical diagnostic purposes and treatment purposes, namely, biological preparation in the nature of viral vectors and non-viral transfection agents being reagents for medical use based on linear or branched polyethyleneimines, nano-particles, lipophilic particles, peptides, micelles, dendrimers, hydrogels, synthetic or naturally derived exosomes, polymeric composition, or virus-like particles, that facilitate the delivery of a wide range of pharmaceuticals or nucleic acid sequences into human and animal bodies to detect and treat infectious viral-based diseases, infectious bacterial-based diseases, infectious fungal-based diseases, autoimmune diseases, allergies, heart- and vascular-based diseases, cerebrovascular disease, neurological disorders and diseases, metabolic diseases, genetic diseases, blood-based diseases, kidney diseases, pancreatic diseases, muscular and neuromuscular diseases, and gastrointestinal diseases and conditions, and for eliminating toxins in body tissue and fluids
  • GS0101: Medical devices for delivering pharmaceutical preparations and genetic material into human or animal tissues and cells for the purpose of diagnosis of disease or treatment of disease, pathogens, and toxins in humans and animals, namely, syringes, implantable drug delivery pumps with and without catheters, infusion pumps, drug delivery catheters, infusion sets, cannulas, transdermal drug delivery patches, autoinjectors being injection devices for administering drugs, electroporators being electromagnetic drug delivery apparatus for medical use, and inhaled delivery devices being inhalers for medical purposes, all the forgoing sold empty and without medication; Medical devices for the delivery of pharmaceutical preparations and genetic material into human or animal tissues and cells for the purpose of diagnosis of disease or treatment of disease, pathogens, and toxins in humans and animals, namely, inhalers for medical purposes, sold empty and drug delivery patches sold without medication; Medical instruments for use in treating infectious diseases and for eliminating pathogens and toxins in humans and animals
Case File Event Statements
  • 1/31/2023 - 2 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 2/15/2023 - 2 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 10/26/2023 - a year ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 11/2/2023 - a year ago
    4 - PRIORITY ACTION WRITTEN Type: CPRA
  • 11/2/2023 - a year ago
    5 - PRIORITY ACTION E-MAILED Type: GPRA
  • 11/2/2023 - a year ago
    6 - NOTIFICATION OF PRIORITY ACTION E-MAILED Type: GPRN
  • 1/18/2024 - a year ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 1/18/2024 - a year ago
    8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 1/19/2024 - a year ago
    9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 2/16/2024 - a year ago
    10 - FINAL REFUSAL WRITTEN Type: CNFR
  • 2/16/2024 - a year ago
    11 - FINAL REFUSAL E-MAILED Type: GNFR
  • 2/16/2024 - a year ago
    12 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 5/3/2024 - 10 months ago
    14 - APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Type: XELG
  • 5/3/2024 - 10 months ago
    13 - APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Type: XELR
  • 8/14/2024 - 6 months ago
    16 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 8/14/2024 - 6 months ago
    17 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 8/14/2024 - 6 months ago
    15 - TEAS REQUEST FOR RECONSIDERATION RECEIVED Type: ERFR
  • 9/6/2024 - 6 months ago
    18 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 9/25/2024 - 5 months ago
    19 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 11/26/2024 - 3 months ago
    22 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 10/15/2024 - 4 months ago
    20 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 10/15/2024 - 4 months ago
    21 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 3/6/2025 - 4 days ago
    23 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 3/6/2025 - 4 days ago
    24 - SOU EXTENSION 1 FILED Type: EXT1
  • 3/7/2025 - 3 days ago
    25 - SOU EXTENSION 1 GRANTED Type: EX1G
  • 3/7/2025 - 3 days ago
    26 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA